IGVFFI5753CWJL

1{
2    "@context": "/terms/",
3    "@id": "/tabular-files/IGVFFI5753CWJL/",
4    "@type": [
5        "TabularFile",
6        "File",
7        "Item"
8    ],
9    "accession": "IGVFFI5753CWJL",
10    "aliases": [
11        "jesse-engreitz:PPIF_promoter_8mer_insertion_Jurkat-Stimulation_Variant-EFFECTS_File_Standardized"
12    ],
13    "assay_titles": [
14        "Variant-EFFECTS"
15    ],
16    "assembly": "GRCh38",
17    "audit": {},
18    "award": {
19        "@id": "/awards/HG011972/",
20        "component": "functional characterization"
21    },
22    "barcode_map_for": [],
23    "checkfiles_version": "v20",
24    "content_md5sum": "bd7eec77e9fd6ce5f2e5a10969e3c28d",
25    "content_type": "variant effects",
26    "controlled_access": false,
27    "creation_timestamp": "2025-03-29T00:21:01.672800+00:00",
28    "derived_from": [
29        "/tabular-files/IGVFFI7903UEWZ/"
30    ],
31    "derived_manually": true,
32    "description": "Manually standardized output of Variant-EFFECTS pipeline, formatted for GRCh38 with SPDI variant IDs",
33    "file_format": "tsv",
34    "file_format_specifications": [
35        {
36            "@id": "/documents/9d0ad6fb-777c-4cb6-a1c4-8ff7a41b17a1/",
37            "description": "This file type describes results from genome editing experiments that measure the effect of a variant on an endogenous gene in the genome."
38        }
39    ],
40    "file_set": {
41        "@id": "/analysis-sets/IGVFDS1863TJOE/",
42        "@type": [
43            "AnalysisSet",
44            "FileSet",
45            "Item"
46        ],
47        "accession": "IGVFDS1863TJOE",
48        "data_use_limitation_summaries": [
49            "no certificate"
50        ],
51        "file_set_type": "principal analysis",
52        "samples": [
53            {
54                "@id": "/in-vitro-systems/IGVFSM3005IBKC/",
55                "@type": [
56                    "InVitroSystem",
57                    "Biosample",
58                    "Sample",
59                    "Item"
60                ],
61                "accession": "IGVFSM3005IBKC",
62                "classifications": [
63                    "cell line"
64                ],
65                "modifications": [
66                    {
67                        "@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
68                        "modality": "prime editing",
69                        "status": "released",
70                        "summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
71                    }
72                ],
73                "sample_terms": [
74                    {
75                        "@id": "/sample-terms/EFO_0002796/",
76                        "status": "released",
77                        "term_name": "Jurkat"
78                    }
79                ],
80                "status": "released",
81                "summary": "Homo sapiens (male) Jurkat cell line (sorting details: FACS bin for 55-65% expression of PPIF) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
82                "taxa": "Homo sapiens",
83                "treatments": [
84                    {
85                        "@id": "/treatments/df02c0d4-f796-4f77-bfbc-388cdbfcc615/",
86                        "purpose": "stimulation",
87                        "status": "released",
88                        "summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours",
89                        "treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
90                    },
91                    {
92                        "@id": "/treatments/42b3c61d-38de-4bd2-bb39-33c125a417cb/",
93                        "purpose": "stimulation",
94                        "status": "released",
95                        "summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours",
96                        "treatment_term_name": "phorbol 13-acetate 12-myristate"
97                    }
98                ]
99            },
100            {
101                "@id": "/in-vitro-systems/IGVFSM6063ZQHX/",
102                "@type": [
103                    "InVitroSystem",
104                    "Biosample",
105                    "Sample",
106                    "Item"
107                ],
108                "accession": "IGVFSM6063ZQHX",
109                "classifications": [
110                    "cell line"
111                ],
112                "modifications": [
113                    {
114                        "@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
115                        "modality": "prime editing",
116                        "status": "released",
117                        "summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
118                    }
119                ],
120                "sample_terms": [
121                    {
122                        "@id": "/sample-terms/EFO_0002796/",
123                        "status": "released",
124                        "term_name": "Jurkat"
125                    }
126                ],
127                "status": "released",
128                "summary": "Homo sapiens (male) Jurkat cell line (sorting details: FACS bin for 35-45% expression of PPIF) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
129                "taxa": "Homo sapiens",
130                "treatments": [
131                    {
132                        "@id": "/treatments/df02c0d4-f796-4f77-bfbc-388cdbfcc615/",
133                        "purpose": "stimulation",
134                        "status": "released",
135                        "summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours",
136                        "treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
137                    },
138                    {
139                        "@id": "/treatments/42b3c61d-38de-4bd2-bb39-33c125a417cb/",
140                        "purpose": "stimulation",
141                        "status": "released",
142                        "summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours",
143                        "treatment_term_name": "phorbol 13-acetate 12-myristate"
144                    }
145                ]
146            },
147            {
148                "@id": "/in-vitro-systems/IGVFSM3390LNPT/",
149                "@type": [
150                    "InVitroSystem",
151                    "Biosample",
152                    "Sample",
153                    "Item"
154                ],
155                "accession": "IGVFSM3390LNPT",
156                "classifications": [
157                    "cell line"
158                ],
159                "modifications": [
160                    {
161                        "@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
162                        "modality": "prime editing",
163                        "status": "released",
164                        "summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
165                    }
166                ],
167                "sample_terms": [
168                    {
169                        "@id": "/sample-terms/EFO_0002796/",
170                        "status": "released",
171                        "term_name": "Jurkat"
172                    }
173                ],
174                "status": "released",
175                "summary": "Homo sapiens (male) Jurkat cell line (sorting details: FACS bin for 0-10% expression of PPIF) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
176                "taxa": "Homo sapiens",
177                "treatments": [
178                    {
179                        "@id": "/treatments/df02c0d4-f796-4f77-bfbc-388cdbfcc615/",
180                        "purpose": "stimulation",
181                        "status": "released",
182                        "summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours",
183                        "treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
184                    },
185                    {
186                        "@id": "/treatments/42b3c61d-38de-4bd2-bb39-33c125a417cb/",
187                        "purpose": "stimulation",
188                        "status": "released",
189                        "summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours",
190                        "treatment_term_name": "phorbol 13-acetate 12-myristate"
191                    }
192                ]
193            },
194            {
195                "@id": "/in-vitro-systems/IGVFSM5988GKVB/",
196                "@type": [
197                    "InVitroSystem",
198                    "Biosample",
199                    "Sample",
200                    "Item"
201                ],
202                "accession": "IGVFSM5988GKVB",
203                "classifications": [
204                    "cell line"
205                ],
206                "modifications": [
207                    {
208                        "@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
209                        "modality": "prime editing",
210                        "status": "released",
211                        "summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
212                    }
213                ],
214                "sample_terms": [
215                    {
216                        "@id": "/sample-terms/EFO_0002796/",
217                        "status": "released",
218                        "term_name": "Jurkat"
219                    }
220                ],
221                "status": "released",
222                "summary": "Homo sapiens (male) Jurkat cell line (sorting details: FACS bin for 80-90% expression of PPIF) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
223                "taxa": "Homo sapiens",
224                "treatments": [
225                    {
226                        "@id": "/treatments/df02c0d4-f796-4f77-bfbc-388cdbfcc615/",
227                        "purpose": "stimulation",
228                        "status": "released",
229                        "summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours",
230                        "treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
231                    },
232                    {
233                        "@id": "/treatments/42b3c61d-38de-4bd2-bb39-33c125a417cb/",
234                        "purpose": "stimulation",
235                        "status": "released",
236                        "summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours",
237                        "treatment_term_name": "phorbol 13-acetate 12-myristate"
238                    }
239                ]
240            },
241            {
242                "@id": "/in-vitro-systems/IGVFSM1974SMNN/",
243                "@type": [
244                    "InVitroSystem",
245                    "Biosample",
246                    "Sample",
247                    "Item"
248                ],
249                "accession": "IGVFSM1974SMNN",
250                "classifications": [
251                    "cell line"
252                ],
253                "modifications": [
254                    {
255                        "@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
256                        "modality": "prime editing",
257                        "status": "released",
258                        "summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
259                    }
260                ],
261                "sample_terms": [
262                    {
263                        "@id": "/sample-terms/EFO_0002796/",
264                        "status": "released",
265                        "term_name": "Jurkat"
266                    }
267                ],
268                "status": "released",
269                "summary": "Homo sapiens (male) Jurkat cell line (sorting details: FACS bin for 80-90% expression of PPIF) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
270                "taxa": "Homo sapiens",
271                "treatments": [
272                    {
273                        "@id": "/treatments/df02c0d4-f796-4f77-bfbc-388cdbfcc615/",
274                        "purpose": "stimulation",
275                        "status": "released",
276                        "summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours",
277                        "treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
278                    },
279                    {
280                        "@id": "/treatments/42b3c61d-38de-4bd2-bb39-33c125a417cb/",
281                        "purpose": "stimulation",
282                        "status": "released",
283                        "summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours",
284                        "treatment_term_name": "phorbol 13-acetate 12-myristate"
285                    }
286                ]
287            },
288            {
289                "@id": "/in-vitro-systems/IGVFSM8232SHRI/",
290                "@type": [
291                    "InVitroSystem",
292                    "Biosample",
293                    "Sample",
294                    "Item"
295                ],
296                "accession": "IGVFSM8232SHRI",
297                "classifications": [
298                    "cell line"
299                ],
300                "modifications": [
301                    {
302                        "@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
303                        "modality": "prime editing",
304                        "status": "released",
305                        "summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
306                    }
307                ],
308                "sample_terms": [
309                    {
310                        "@id": "/sample-terms/EFO_0002796/",
311                        "status": "released",
312                        "term_name": "Jurkat"
313                    }
314                ],
315                "status": "released",
316                "summary": "Homo sapiens (male) Jurkat cell line (sorting details: FACS bin for 35-45% expression of PPIF) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
317                "taxa": "Homo sapiens",
318                "treatments": [
319                    {
320                        "@id": "/treatments/df02c0d4-f796-4f77-bfbc-388cdbfcc615/",
321                        "purpose": "stimulation",
322                        "status": "released",
323                        "summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours",
324                        "treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
325                    },
326                    {
327                        "@id": "/treatments/42b3c61d-38de-4bd2-bb39-33c125a417cb/",
328                        "purpose": "stimulation",
329                        "status": "released",
330                        "summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours",
331                        "treatment_term_name": "phorbol 13-acetate 12-myristate"
332                    }
333                ]
334            },
335            {
336                "@id": "/in-vitro-systems/IGVFSM9490SYQE/",
337                "@type": [
338                    "InVitroSystem",
339                    "Biosample",
340                    "Sample",
341                    "Item"
342                ],
343                "accession": "IGVFSM9490SYQE",
344                "classifications": [
345                    "cell line"
346                ],
347                "modifications": [
348                    {
349                        "@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
350                        "modality": "prime editing",
351                        "status": "released",
352                        "summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
353                    }
354                ],
355                "sample_terms": [
356                    {
357                        "@id": "/sample-terms/EFO_0002796/",
358                        "status": "released",
359                        "term_name": "Jurkat"
360                    }
361                ],
362                "status": "released",
363                "summary": "Homo sapiens (male) Jurkat cell line (sorting details: FACS bin for 80-90% expression of PPIF) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
364                "taxa": "Homo sapiens",
365                "treatments": [
366                    {
367                        "@id": "/treatments/df02c0d4-f796-4f77-bfbc-388cdbfcc615/",
368                        "purpose": "stimulation",
369                        "status": "released",
370                        "summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours",
371                        "treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
372                    },
373                    {
374                        "@id": "/treatments/42b3c61d-38de-4bd2-bb39-33c125a417cb/",
375                        "purpose": "stimulation",
376                        "status": "released",
377                        "summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours",
378                        "treatment_term_name": "phorbol 13-acetate 12-myristate"
379                    }
380                ]
381            },
382            {
383                "@id": "/in-vitro-systems/IGVFSM7935BTPN/",
384                "@type": [
385                    "InVitroSystem",
386                    "Biosample",
387                    "Sample",
388                    "Item"
389                ],
390                "accession": "IGVFSM7935BTPN",
391                "classifications": [
392                    "cell line"
393                ],
394                "modifications": [
395                    {
396                        "@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
397                        "modality": "prime editing",
398                        "status": "released",
399                        "summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
400                    }
401                ],
402                "sample_terms": [
403                    {
404                        "@id": "/sample-terms/EFO_0002796/",
405                        "status": "released",
406                        "term_name": "Jurkat"
407                    }
408                ],
409                "status": "released",
410                "summary": "Homo sapiens (male) Jurkat cell line (sorting details: FACS bin for 35-45% expression of PPIF) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
411                "taxa": "Homo sapiens",
412                "treatments": [
413                    {
414                        "@id": "/treatments/df02c0d4-f796-4f77-bfbc-388cdbfcc615/",
415                        "purpose": "stimulation",
416                        "status": "released",
417                        "summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours",
418                        "treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
419                    },
420                    {
421                        "@id": "/treatments/42b3c61d-38de-4bd2-bb39-33c125a417cb/",
422                        "purpose": "stimulation",
423                        "status": "released",
424                        "summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours",
425                        "treatment_term_name": "phorbol 13-acetate 12-myristate"
426                    }
427                ]
428            },
429            {
430                "@id": "/in-vitro-systems/IGVFSM9986DXPM/",
431                "@type": [
432                    "InVitroSystem",
433                    "Biosample",
434                    "Sample",
435                    "Item"
436                ],
437                "accession": "IGVFSM9986DXPM",
438                "classifications": [
439                    "cell line"
440                ],
441                "modifications": [
442                    {
443                        "@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
444                        "modality": "prime editing",
445                        "status": "released",
446                        "summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
447                    }
448                ],
449                "sample_terms": [
450                    {
451                        "@id": "/sample-terms/EFO_0002796/",
452                        "status": "released",
453                        "term_name": "Jurkat"
454                    }
455                ],
456                "status": "released",
457                "summary": "Homo sapiens (male) Jurkat cell line (sorting details: FACS bin for 0-10% expression of PPIF) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
458                "taxa": "Homo sapiens",
459                "treatments": [
460                    {
461                        "@id": "/treatments/df02c0d4-f796-4f77-bfbc-388cdbfcc615/",
462                        "purpose": "stimulation",
463                        "status": "released",
464                        "summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours",
465                        "treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
466                    },
467                    {
468                        "@id": "/treatments/42b3c61d-38de-4bd2-bb39-33c125a417cb/",
469                        "purpose": "stimulation",
470                        "status": "released",
471                        "summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours",
472                        "treatment_term_name": "phorbol 13-acetate 12-myristate"
473                    }
474                ]
475            },
476            {
477                "@id": "/in-vitro-systems/IGVFSM0453ERNS/",
478                "@type": [
479                    "InVitroSystem",
480                    "Biosample",
481                    "Sample",
482                    "Item"
483                ],
484                "accession": "IGVFSM0453ERNS",
485                "classifications": [
486                    "cell line"
487                ],
488                "modifications": [
489                    {
490                        "@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
491                        "modality": "prime editing",
492                        "status": "released",
493                        "summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
494                    }
495                ],
496                "sample_terms": [
497                    {
498                        "@id": "/sample-terms/EFO_0002796/",
499                        "status": "released",
500                        "term_name": "Jurkat"
501                    }
502                ],
503                "status": "released",
504                "summary": "Homo sapiens (male) Jurkat cell line (sorting details: FACS bin for 80-90% expression of PPIF) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
505                "taxa": "Homo sapiens",
506                "treatments": [
507                    {
508                        "@id": "/treatments/df02c0d4-f796-4f77-bfbc-388cdbfcc615/",
509                        "purpose": "stimulation",
510                        "status": "released",
511                        "summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours",
512                        "treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
513                    },
514                    {
515                        "@id": "/treatments/42b3c61d-38de-4bd2-bb39-33c125a417cb/",
516                        "purpose": "stimulation",
517                        "status": "released",
518                        "summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours",
519                        "treatment_term_name": "phorbol 13-acetate 12-myristate"
520                    }
521                ]
522            },
523            {
524                "@id": "/in-vitro-systems/IGVFSM6807ZRBS/",
525                "@type": [
526                    "InVitroSystem",
527                    "Biosample",
528                    "Sample",
529                    "Item"
530                ],
531                "accession": "IGVFSM6807ZRBS",
532                "classifications": [
533                    "cell line"
534                ],
535                "modifications": [
536                    {
537                        "@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
538                        "modality": "prime editing",
539                        "status": "released",
540                        "summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
541                    }
542                ],
543                "sample_terms": [
544                    {
545                        "@id": "/sample-terms/EFO_0002796/",
546                        "status": "released",
547                        "term_name": "Jurkat"
548                    }
549                ],
550                "status": "released",
551                "summary": "Homo sapiens (male) Jurkat cell line (sorting details: FACS bin for 80-90% expression of PPIF) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
552                "taxa": "Homo sapiens",
553                "treatments": [
554                    {
555                        "@id": "/treatments/df02c0d4-f796-4f77-bfbc-388cdbfcc615/",
556                        "purpose": "stimulation",
557                        "status": "released",
558                        "summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours",
559                        "treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
560                    },
561                    {
562                        "@id": "/treatments/42b3c61d-38de-4bd2-bb39-33c125a417cb/",
563                        "purpose": "stimulation",
564                        "status": "released",
565                        "summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours",
566                        "treatment_term_name": "phorbol 13-acetate 12-myristate"
567                    }
568                ]
569            },
570            {
571                "@id": "/in-vitro-systems/IGVFSM8422VLKL/",
572                "@type": [
573                    "InVitroSystem",
574                    "Biosample",
575                    "Sample",
576                    "Item"
577                ],
578                "accession": "IGVFSM8422VLKL",
579                "classifications": [
580                    "cell line"
581                ],
582                "modifications": [
583                    {
584                        "@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
585                        "modality": "prime editing",
586                        "status": "released",
587                        "summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
588                    }
589                ],
590                "sample_terms": [
591                    {
592                        "@id": "/sample-terms/EFO_0002796/",
593                        "status": "released",
594                        "term_name": "Jurkat"
595                    }
596                ],
597                "status": "released",
598                "summary": "Homo sapiens (male) Jurkat cell line treated with 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
599                "taxa": "Homo sapiens",
600                "treatments": [
601                    {
602                        "@id": "/treatments/df02c0d4-f796-4f77-bfbc-388cdbfcc615/",
603                        "purpose": "stimulation",
604                        "status": "released",
605                        "summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours",
606                        "treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
607                    },
608                    {
609                        "@id": "/treatments/42b3c61d-38de-4bd2-bb39-33c125a417cb/",
610                        "purpose": "stimulation",
611                        "status": "released",
612                        "summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours",
613                        "treatment_term_name": "phorbol 13-acetate 12-myristate"
614                    }
615                ]
616            },
617            {
618                "@id": "/in-vitro-systems/IGVFSM1037DJMF/",
619                "@type": [
620                    "InVitroSystem",
621                    "Biosample",
622                    "Sample",
623                    "Item"
624                ],
625                "accession": "IGVFSM1037DJMF",
626                "classifications": [
627                    "cell line"
628                ],
629                "modifications": [
630                    {
631                        "@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
632                        "modality": "prime editing",
633                        "status": "released",
634                        "summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
635                    }
636                ],
637                "sample_terms": [
638                    {
639                        "@id": "/sample-terms/EFO_0002796/",
640                        "status": "released",
641                        "term_name": "Jurkat"
642                    }
643                ],
644                "status": "released",
645                "summary": "Homo sapiens (male) Jurkat cell line (sorting details: FACS bin for 90-100% expression of PPIF) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
646                "taxa": "Homo sapiens",
647                "treatments": [
648                    {
649                        "@id": "/treatments/df02c0d4-f796-4f77-bfbc-388cdbfcc615/",
650                        "purpose": "stimulation",
651                        "status": "released",
652                        "summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours",
653                        "treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
654                    },
655                    {
656                        "@id": "/treatments/42b3c61d-38de-4bd2-bb39-33c125a417cb/",
657                        "purpose": "stimulation",
658                        "status": "released",
659                        "summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours",
660                        "treatment_term_name": "phorbol 13-acetate 12-myristate"
661                    }
662                ]
663            },
664            {
665                "@id": "/in-vitro-systems/IGVFSM7763LCFC/",
666                "@type": [
667                    "InVitroSystem",
668                    "Biosample",
669                    "Sample",
670                    "Item"
671                ],
672                "accession": "IGVFSM7763LCFC",
673                "classifications": [
674                    "cell line"
675                ],
676                "modifications": [
677                    {
678                        "@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
679                        "modality": "prime editing",
680                        "status": "released",
681                        "summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
682                    }
683                ],
684                "sample_terms": [
685                    {
686                        "@id": "/sample-terms/EFO_0002796/",
687                        "status": "released",
688                        "term_name": "Jurkat"
689                    }
690                ],
691                "status": "released",
692                "summary": "Homo sapiens (male) Jurkat cell line (sorting details: FACS bin for 55-65% expression of PPIF) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
693                "taxa": "Homo sapiens",
694                "treatments": [
695                    {
696                        "@id": "/treatments/df02c0d4-f796-4f77-bfbc-388cdbfcc615/",
697                        "purpose": "stimulation",
698                        "status": "released",
699                        "summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours",
700                        "treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
701                    },
702                    {
703                        "@id": "/treatments/42b3c61d-38de-4bd2-bb39-33c125a417cb/",
704                        "purpose": "stimulation",
705                        "status": "released",
706                        "summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours",
707                        "treatment_term_name": "phorbol 13-acetate 12-myristate"
708                    }
709                ]
710            },
711            {
712                "@id": "/in-vitro-systems/IGVFSM8638GWPD/",
713                "@type": [
714                    "InVitroSystem",
715                    "Biosample",
716                    "Sample",
717                    "Item"
718                ],
719                "accession": "IGVFSM8638GWPD",
720                "classifications": [
721                    "cell line"
722                ],
723                "modifications": [
724                    {
725                        "@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
726                        "modality": "prime editing",
727                        "status": "released",
728                        "summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
729                    }
730                ],
731                "sample_terms": [
732                    {
733                        "@id": "/sample-terms/EFO_0002796/",
734                        "status": "released",
735                        "term_name": "Jurkat"
736                    }
737                ],
738                "status": "released",
739                "summary": "Homo sapiens (male) Jurkat cell line (sorting details: FACS bin for 90-100% expression of PPIF) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
740                "taxa": "Homo sapiens",
741                "treatments": [
742                    {
743                        "@id": "/treatments/df02c0d4-f796-4f77-bfbc-388cdbfcc615/",
744                        "purpose": "stimulation",
745                        "status": "released",
746                        "summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours",
747                        "treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
748                    },
749                    {
750                        "@id": "/treatments/42b3c61d-38de-4bd2-bb39-33c125a417cb/",
751                        "purpose": "stimulation",
752                        "status": "released",
753                        "summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours",
754                        "treatment_term_name": "phorbol 13-acetate 12-myristate"
755                    }
756                ]
757            },
758            {
759                "@id": "/in-vitro-systems/IGVFSM1972TKGI/",
760                "@type": [
761                    "InVitroSystem",
762                    "Biosample",
763                    "Sample",
764                    "Item"
765                ],
766                "accession": "IGVFSM1972TKGI",
767                "classifications": [
768                    "cell line"
769                ],
770                "modifications": [
771                    {
772                        "@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
773                        "modality": "prime editing",
774                        "status": "released",
775                        "summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
776                    }
777                ],
778                "sample_terms": [
779                    {
780                        "@id": "/sample-terms/EFO_0002796/",
781                        "status": "released",
782                        "term_name": "Jurkat"
783                    }
784                ],
785                "status": "released",
786                "summary": "Homo sapiens (male) Jurkat cell line treated with 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
787                "taxa": "Homo sapiens",
788                "treatments": [
789                    {
790                        "@id": "/treatments/df02c0d4-f796-4f77-bfbc-388cdbfcc615/",
791                        "purpose": "stimulation",
792                        "status": "released",
793                        "summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours",
794                        "treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
795                    },
796                    {
797                        "@id": "/treatments/42b3c61d-38de-4bd2-bb39-33c125a417cb/",
798                        "purpose": "stimulation",
799                        "status": "released",
800                        "summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours",
801                        "treatment_term_name": "phorbol 13-acetate 12-myristate"
802                    }
803                ]
804            },
805            {
806                "@id": "/in-vitro-systems/IGVFSM9615VPZF/",
807                "@type": [
808                    "InVitroSystem",
809                    "Biosample",
810                    "Sample",
811                    "Item"
812                ],
813                "accession": "IGVFSM9615VPZF",
814                "classifications": [
815                    "cell line"
816                ],
817                "modifications": [
818                    {
819                        "@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
820                        "modality": "prime editing",
821                        "status": "released",
822                        "summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
823                    }
824                ],
825                "sample_terms": [
826                    {
827                        "@id": "/sample-terms/EFO_0002796/",
828                        "status": "released",
829                        "term_name": "Jurkat"
830                    }
831                ],
832                "status": "released",
833                "summary": "Homo sapiens (male) Jurkat cell line (sorting details: FACS bin for 55-65% expression of PPIF) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
834                "taxa": "Homo sapiens",
835                "treatments": [
836                    {
837                        "@id": "/treatments/df02c0d4-f796-4f77-bfbc-388cdbfcc615/",
838                        "purpose": "stimulation",
839                        "status": "released",
840                        "summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours",
841                        "treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
842                    },
843                    {
844                        "@id": "/treatments/42b3c61d-38de-4bd2-bb39-33c125a417cb/",
845                        "purpose": "stimulation",
846                        "status": "released",
847                        "summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours",
848                        "treatment_term_name": "phorbol 13-acetate 12-myristate"
849                    }
850                ]
851            },
852            {
853                "@id": "/in-vitro-systems/IGVFSM7055YGLH/",
854                "@type": [
855                    "InVitroSystem",
856                    "Biosample",
857                    "Sample",
858                    "Item"
859                ],
860                "accession": "IGVFSM7055YGLH",
861                "classifications": [
862                    "cell line"
863                ],
864                "modifications": [
865                    {
866                        "@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
867                        "modality": "prime editing",
868                        "status": "released",
869                        "summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
870                    }
871                ],
872                "sample_terms": [
873                    {
874                        "@id": "/sample-terms/EFO_0002796/",
875                        "status": "released",
876                        "term_name": "Jurkat"
877                    }
878                ],
879                "status": "released",
880                "summary": "Homo sapiens (male) Jurkat cell line (sorting details: FACS bin for 55-65% expression of PPIF) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
881                "taxa": "Homo sapiens",
882                "treatments": [
883                    {
884                        "@id": "/treatments/df02c0d4-f796-4f77-bfbc-388cdbfcc615/",
885                        "purpose": "stimulation",
886                        "status": "released",
887                        "summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours",
888                        "treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
889                    },
890                    {
891                        "@id": "/treatments/42b3c61d-38de-4bd2-bb39-33c125a417cb/",
892                        "purpose": "stimulation",
893                        "status": "released",
894                        "summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours",
895                        "treatment_term_name": "phorbol 13-acetate 12-myristate"
896                    }
897                ]
898            },
899            {
900                "@id": "/in-vitro-systems/IGVFSM1944NSGS/",
901                "@type": [
902                    "InVitroSystem",
903                    "Biosample",
904                    "Sample",
905                    "Item"
906                ],
907                "accession": "IGVFSM1944NSGS",
908                "classifications": [
909                    "cell line"
910                ],
911                "modifications": [
912                    {
913                        "@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
914                        "modality": "prime editing",
915                        "status": "released",
916                        "summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
917                    }
918                ],
919                "sample_terms": [
920                    {
921                        "@id": "/sample-terms/EFO_0002796/",
922                        "status": "released",
923                        "term_name": "Jurkat"
924                    }
925                ],
926                "status": "released",
927                "summary": "Homo sapiens (male) Jurkat cell line (sorting details: FACS bin for 0-10% expression of PPIF) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
928                "taxa": "Homo sapiens",
929                "treatments": [
930                    {
931                        "@id": "/treatments/df02c0d4-f796-4f77-bfbc-388cdbfcc615/",
932                        "purpose": "stimulation",
933                        "status": "released",
934                        "summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours",
935                        "treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
936                    },
937                    {
938                        "@id": "/treatments/42b3c61d-38de-4bd2-bb39-33c125a417cb/",
939                        "purpose": "stimulation",
940                        "status": "released",
941                        "summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours",
942                        "treatment_term_name": "phorbol 13-acetate 12-myristate"
943                    }
944                ]
945            },
946            {
947                "@id": "/in-vitro-systems/IGVFSM7050AWXV/",
948                "@type": [
949                    "InVitroSystem",
950                    "Biosample",
951                    "Sample",
952                    "Item"
953                ],
954                "accession": "IGVFSM7050AWXV",
955                "classifications": [
956                    "cell line"
957                ],
958                "modifications": [
959                    {
960                        "@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
961                        "modality": "prime editing",
962                        "status": "released",
963                        "summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
964                    }
965                ],
966                "sample_terms": [
967                    {
968                        "@id": "/sample-terms/EFO_0002796/",
969                        "status": "released",
970                        "term_name": "Jurkat"
971                    }
972                ],
973                "status": "released",
974                "summary": "Homo sapiens (male) Jurkat cell line (sorting details: FACS bin for 55-65% expression of PPIF) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
975                "taxa": "Homo sapiens",
976                "treatments": [
977                    {
978                        "@id": "/treatments/df02c0d4-f796-4f77-bfbc-388cdbfcc615/",
979                        "purpose": "stimulation",
980                        "status": "released",
981                        "summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours",
982                        "treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
983                    },
984                    {
985                        "@id": "/treatments/42b3c61d-38de-4bd2-bb39-33c125a417cb/",
986                        "purpose": "stimulation",
987                        "status": "released",
988                        "summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours",
989                        "treatment_term_name": "phorbol 13-acetate 12-myristate"
990                    }
991                ]
992            },
993            {
994                "@id": "/in-vitro-systems/IGVFSM0082DAAR/",
995                "@type": [
996                    "InVitroSystem",
997                    "Biosample",
998                    "Sample",
999                    "Item"
1000                ],
1001                "accession": "IGVFSM0082DAAR",
1002                "classifications": [
1003                    "cell line"
1004                ],
1005                "modifications": [
1006                    {
1007                        "@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
1008                        "modality": "prime editing",
1009                        "status": "released",
1010                        "summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
1011                    }
1012                ],
1013                "sample_terms": [
1014                    {
1015                        "@id": "/sample-terms/EFO_0002796/",
1016                        "status": "released",
1017                        "term_name": "Jurkat"
1018                    }
1019                ],
1020                "status": "released",
1021                "summary": "Homo sapiens (male) Jurkat cell line (sorting details: FACS bin for 0-10% expression of PPIF) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
1022                "taxa": "Homo sapiens",
1023                "treatments": [
1024                    {
1025                        "@id": "/treatments/df02c0d4-f796-4f77-bfbc-388cdbfcc615/",
1026                        "purpose": "stimulation",
1027                        "status": "released",
1028                        "summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours",
1029                        "treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
1030                    },
1031                    {
1032                        "@id": "/treatments/42b3c61d-38de-4bd2-bb39-33c125a417cb/",
1033                        "purpose": "stimulation",
1034                        "status": "released",
1035                        "summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours",
1036                        "treatment_term_name": "phorbol 13-acetate 12-myristate"
1037                    }
1038                ]
1039            },
1040            {
1041                "@id": "/in-vitro-systems/IGVFSM6792CERQ/",
1042                "@type": [
1043                    "InVitroSystem",
1044                    "Biosample",
1045                    "Sample",
1046                    "Item"
1047                ],
1048                "accession": "IGVFSM6792CERQ",
1049                "classifications": [
1050                    "cell line"
1051                ],
1052                "modifications": [
1053                    {
1054                        "@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
1055                        "modality": "prime editing",
1056                        "status": "released",
1057                        "summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
1058                    }
1059                ],
1060                "sample_terms": [
1061                    {
1062                        "@id": "/sample-terms/EFO_0002796/",
1063                        "status": "released",
1064                        "term_name": "Jurkat"
1065                    }
1066                ],
1067                "status": "released",
1068                "summary": "Homo sapiens (male) Jurkat cell line (sorting details: FACS bin for 80-90% expression of PPIF) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
1069                "taxa": "Homo sapiens",
1070                "treatments": [
1071                    {
1072                        "@id": "/treatments/df02c0d4-f796-4f77-bfbc-388cdbfcc615/",
1073                        "purpose": "stimulation",
1074                        "status": "released",
1075                        "summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours",
1076                        "treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
1077                    },
1078                    {
1079                        "@id": "/treatments/42b3c61d-38de-4bd2-bb39-33c125a417cb/",
1080                        "purpose": "stimulation",
1081                        "status": "released",
1082                        "summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours",
1083                        "treatment_term_name": "phorbol 13-acetate 12-myristate"
1084                    }
1085                ]
1086            },
1087            {
1088                "@id": "/in-vitro-systems/IGVFSM8328COCO/",
1089                "@type": [
1090                    "InVitroSystem",
1091                    "Biosample",
1092                    "Sample",
1093                    "Item"
1094                ],
1095                "accession": "IGVFSM8328COCO",
1096                "classifications": [
1097                    "cell line"
1098                ],
1099                "modifications": [
1100                    {
1101                        "@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
1102                        "modality": "prime editing",
1103                        "status": "released",
1104                        "summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
1105                    }
1106                ],
1107                "sample_terms": [
1108                    {
1109                        "@id": "/sample-terms/EFO_0002796/",
1110                        "status": "released",
1111                        "term_name": "Jurkat"
1112                    }
1113                ],
1114                "status": "released",
1115                "summary": "Homo sapiens (male) Jurkat cell line treated with 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
1116                "taxa": "Homo sapiens",
1117                "treatments": [
1118                    {
1119                        "@id": "/treatments/df02c0d4-f796-4f77-bfbc-388cdbfcc615/",
1120                        "purpose": "stimulation",
1121                        "status": "released",
1122                        "summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours",
1123                        "treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
1124                    },
1125                    {
1126                        "@id": "/treatments/42b3c61d-38de-4bd2-bb39-33c125a417cb/",
1127                        "purpose": "stimulation",
1128                        "status": "released",
1129                        "summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours",
1130                        "treatment_term_name": "phorbol 13-acetate 12-myristate"
1131                    }
1132                ]
1133            },
1134            {
1135                "@id": "/in-vitro-systems/IGVFSM3748XVTQ/",
1136                "@type": [
1137                    "InVitroSystem",
1138                    "Biosample",
1139                    "Sample",
1140                    "Item"
1141                ],
1142                "accession": "IGVFSM3748XVTQ",
1143                "classifications": [
1144                    "cell line"
1145                ],
1146                "modifications": [
1147                    {
1148                        "@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
1149                        "modality": "prime editing",
1150                        "status": "released",
1151                        "summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
1152                    }
1153                ],
1154                "sample_terms": [
1155                    {
1156                        "@id": "/sample-terms/EFO_0002796/",
1157                        "status": "released",
1158                        "term_name": "Jurkat"
1159                    }
1160                ],
1161                "status": "released",
1162                "summary": "Homo sapiens (male) Jurkat cell line (sorting details: FACS bin for 35-45% expression of PPIF) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
1163                "taxa": "Homo sapiens",
1164                "treatments": [
1165                    {
1166                        "@id": "/treatments/df02c0d4-f796-4f77-bfbc-388cdbfcc615/",
1167                        "purpose": "stimulation",
1168                        "status": "released",
1169                        "summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours",
1170                        "treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
1171                    },
1172                    {
1173                        "@id": "/treatments/42b3c61d-38de-4bd2-bb39-33c125a417cb/",
1174                        "purpose": "stimulation",
1175                        "status": "released",
1176                        "summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours",
1177                        "treatment_term_name": "phorbol 13-acetate 12-myristate"
1178                    }
1179                ]
1180            },
1181            {
1182                "@id": "/in-vitro-systems/IGVFSM9814YUSQ/",
1183                "@type": [
1184                    "InVitroSystem",
1185                    "Biosample",
1186                    "Sample",
1187                    "Item"
1188                ],
1189                "accession": "IGVFSM9814YUSQ",
1190                "classifications": [
1191                    "cell line"
1192                ],
1193                "modifications": [
1194                    {
1195                        "@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
1196                        "modality": "prime editing",
1197                        "status": "released",
1198                        "summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
1199                    }
1200                ],
1201                "sample_terms": [
1202                    {
1203                        "@id": "/sample-terms/EFO_0002796/",
1204                        "status": "released",
1205                        "term_name": "Jurkat"
1206                    }
1207                ],
1208                "status": "released",
1209                "summary": "Homo sapiens (male) Jurkat cell line (sorting details: FACS bin for 35-45% expression of PPIF) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
1210                "taxa": "Homo sapiens",
1211                "treatments": [
1212                    {
1213                        "@id": "/treatments/df02c0d4-f796-4f77-bfbc-388cdbfcc615/",
1214                        "purpose": "stimulation",
1215                        "status": "released",
1216                        "summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours",
1217                        "treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
1218                    },
1219                    {
1220                        "@id": "/treatments/42b3c61d-38de-4bd2-bb39-33c125a417cb/",
1221                        "purpose": "stimulation",
1222                        "status": "released",
1223                        "summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours",
1224                        "treatment_term_name": "phorbol 13-acetate 12-myristate"
1225                    }
1226                ]
1227            },
1228            {
1229                "@id": "/in-vitro-systems/IGVFSM0417QXDJ/",
1230                "@type": [
1231                    "InVitroSystem",
1232                    "Biosample",
1233                    "Sample",
1234                    "Item"
1235                ],
1236                "accession": "IGVFSM0417QXDJ",
1237                "classifications": [
1238                    "cell line"
1239                ],
1240                "modifications": [
1241                    {
1242                        "@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
1243                        "modality": "prime editing",
1244                        "status": "released",
1245                        "summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
1246                    }
1247                ],
1248                "sample_terms": [
1249                    {
1250                        "@id": "/sample-terms/EFO_0002796/",
1251                        "status": "released",
1252                        "term_name": "Jurkat"
1253                    }
1254                ],
1255                "status": "released",
1256                "summary": "Homo sapiens (male) Jurkat cell line (sorting details: FACS bin for 90-100% expression of PPIF) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
1257                "taxa": "Homo sapiens",
1258                "treatments": [
1259                    {
1260                        "@id": "/treatments/df02c0d4-f796-4f77-bfbc-388cdbfcc615/",
1261                        "purpose": "stimulation",
1262                        "status": "released",
1263                        "summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours",
1264                        "treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
1265                    },
1266                    {
1267                        "@id": "/treatments/42b3c61d-38de-4bd2-bb39-33c125a417cb/",
1268                        "purpose": "stimulation",
1269                        "status": "released",
1270                        "summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours",
1271                        "treatment_term_name": "phorbol 13-acetate 12-myristate"
1272                    }
1273                ]
1274            },
1275            {
1276                "@id": "/in-vitro-systems/IGVFSM2054NOCA/",
1277                "@type": [
1278                    "InVitroSystem",
1279                    "Biosample",
1280                    "Sample",
1281                    "Item"
1282                ],
1283                "accession": "IGVFSM2054NOCA",
1284                "classifications": [
1285                    "cell line"
1286                ],
1287                "modifications": [
1288                    {
1289                        "@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
1290                        "modality": "prime editing",
1291                        "status": "released",
1292                        "summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
1293                    }
1294                ],
1295                "sample_terms": [
1296                    {
1297                        "@id": "/sample-terms/EFO_0002796/",
1298                        "status": "released",
1299                        "term_name": "Jurkat"
1300                    }
1301                ],
1302                "status": "released",
1303                "summary": "Homo sapiens (male) Jurkat cell line (sorting details: FACS bin for 11-20% expression of PPIF) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
1304                "taxa": "Homo sapiens",
1305                "treatments": [
1306                    {
1307                        "@id": "/treatments/df02c0d4-f796-4f77-bfbc-388cdbfcc615/",
1308                        "purpose": "stimulation",
1309                        "status": "released",
1310                        "summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours",
1311                        "treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
1312                    },
1313                    {
1314                        "@id": "/treatments/42b3c61d-38de-4bd2-bb39-33c125a417cb/",
1315                        "purpose": "stimulation",
1316                        "status": "released",
1317                        "summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours",
1318                        "treatment_term_name": "phorbol 13-acetate 12-myristate"
1319                    }
1320                ]
1321            },
1322            {
1323                "@id": "/in-vitro-systems/IGVFSM9197ZOVQ/",
1324                "@type": [
1325                    "InVitroSystem",
1326                    "Biosample",
1327                    "Sample",
1328                    "Item"
1329                ],
1330                "accession": "IGVFSM9197ZOVQ",
1331                "classifications": [
1332                    "cell line"
1333                ],
1334                "modifications": [
1335                    {
1336                        "@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
1337                        "modality": "prime editing",
1338                        "status": "released",
1339                        "summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
1340                    }
1341                ],
1342                "sample_terms": [
1343                    {
1344                        "@id": "/sample-terms/EFO_0002796/",
1345                        "status": "released",
1346                        "term_name": "Jurkat"
1347                    }
1348                ],
1349                "status": "released",
1350                "summary": "Homo sapiens (male) Jurkat cell line (sorting details: FACS bin for 11-20% expression of PPIF) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
1351                "taxa": "Homo sapiens",
1352                "treatments": [
1353                    {
1354                        "@id": "/treatments/df02c0d4-f796-4f77-bfbc-388cdbfcc615/",
1355                        "purpose": "stimulation",
1356                        "status": "released",
1357                        "summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours",
1358                        "treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
1359                    },
1360                    {
1361                        "@id": "/treatments/42b3c61d-38de-4bd2-bb39-33c125a417cb/",
1362                        "purpose": "stimulation",
1363                        "status": "released",
1364                        "summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours",
1365                        "treatment_term_name": "phorbol 13-acetate 12-myristate"
1366                    }
1367                ]
1368            },
1369            {
1370                "@id": "/in-vitro-systems/IGVFSM3105OTRY/",
1371                "@type": [
1372                    "InVitroSystem",
1373                    "Biosample",
1374                    "Sample",
1375                    "Item"
1376                ],
1377                "accession": "IGVFSM3105OTRY",
1378                "classifications": [
1379                    "cell line"
1380                ],
1381                "modifications": [
1382                    {
1383                        "@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
1384                        "modality": "prime editing",
1385                        "status": "released",
1386                        "summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
1387                    }
1388                ],
1389                "sample_terms": [
1390                    {
1391                        "@id": "/sample-terms/EFO_0002796/",
1392                        "status": "released",
1393                        "term_name": "Jurkat"
1394                    }
1395                ],
1396                "status": "released",
1397                "summary": "Homo sapiens (male) Jurkat cell line (sorting details: FACS bin for 80-90% expression of PPIF) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
1398                "taxa": "Homo sapiens",
1399                "treatments": [
1400                    {
1401                        "@id": "/treatments/df02c0d4-f796-4f77-bfbc-388cdbfcc615/",
1402                        "purpose": "stimulation",
1403                        "status": "released",
1404                        "summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours",
1405                        "treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
1406                    },
1407                    {
1408                        "@id": "/treatments/42b3c61d-38de-4bd2-bb39-33c125a417cb/",
1409                        "purpose": "stimulation",
1410                        "status": "released",
1411                        "summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours",
1412                        "treatment_term_name": "phorbol 13-acetate 12-myristate"
1413                    }
1414                ]
1415            },
1416            {
1417                "@id": "/in-vitro-systems/IGVFSM9186ZLKC/",
1418                "@type": [
1419                    "InVitroSystem",
1420                    "Biosample",
1421                    "Sample",
1422                    "Item"
1423                ],
1424                "accession": "IGVFSM9186ZLKC",
1425                "classifications": [
1426                    "cell line"
1427                ],
1428                "modifications": [
1429                    {
1430                        "@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
1431                        "modality": "prime editing",
1432                        "status": "released",
1433                        "summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
1434                    }
1435                ],
1436                "sample_terms": [
1437                    {
1438                        "@id": "/sample-terms/EFO_0002796/",
1439                        "status": "released",
1440                        "term_name": "Jurkat"
1441                    }
1442                ],
1443                "status": "released",
1444                "summary": "Homo sapiens (male) Jurkat cell line (sorting details: FACS bin for 11-20% expression of PPIF) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
1445                "taxa": "Homo sapiens",
1446                "treatments": [
1447                    {
1448                        "@id": "/treatments/df02c0d4-f796-4f77-bfbc-388cdbfcc615/",
1449                        "purpose": "stimulation",
1450                        "status": "released",
1451                        "summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours",
1452                        "treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
1453                    },
1454                    {
1455                        "@id": "/treatments/42b3c61d-38de-4bd2-bb39-33c125a417cb/",
1456                        "purpose": "stimulation",
1457                        "status": "released",
1458                        "summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours",
1459                        "treatment_term_name": "phorbol 13-acetate 12-myristate"
1460                    }
1461                ]
1462            },
1463            {
1464                "@id": "/in-vitro-systems/IGVFSM6931NDQU/",
1465                "@type": [
1466                    "InVitroSystem",
1467                    "Biosample",
1468                    "Sample",
1469                    "Item"
1470                ],
1471                "accession": "IGVFSM6931NDQU",
1472                "classifications": [
1473                    "cell line"
1474                ],
1475                "modifications": [
1476                    {
1477                        "@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
1478                        "modality": "prime editing",
1479                        "status": "released",
1480                        "summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
1481                    }
1482                ],
1483                "sample_terms": [
1484                    {
1485                        "@id": "/sample-terms/EFO_0002796/",
1486                        "status": "released",
1487                        "term_name": "Jurkat"
1488                    }
1489                ],
1490                "status": "released",
1491                "summary": "Homo sapiens (male) Jurkat cell line treated with 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
1492                "taxa": "Homo sapiens",
1493                "treatments": [
1494                    {
1495                        "@id": "/treatments/df02c0d4-f796-4f77-bfbc-388cdbfcc615/",
1496                        "purpose": "stimulation",
1497                        "status": "released",
1498                        "summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours",
1499                        "treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
1500                    },
1501                    {
1502                        "@id": "/treatments/42b3c61d-38de-4bd2-bb39-33c125a417cb/",
1503                        "purpose": "stimulation",
1504                        "status": "released",
1505                        "summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours",
1506                        "treatment_term_name": "phorbol 13-acetate 12-myristate"
1507                    }
1508                ]
1509            },
1510            {
1511                "@id": "/in-vitro-systems/IGVFSM1022AFZT/",
1512                "@type": [
1513                    "InVitroSystem",
1514                    "Biosample",
1515                    "Sample",
1516                    "Item"
1517                ],
1518                "accession": "IGVFSM1022AFZT",
1519                "classifications": [
1520                    "cell line"
1521                ],
1522                "modifications": [
1523                    {
1524                        "@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
1525                        "modality": "prime editing",
1526                        "status": "released",
1527                        "summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
1528                    }
1529                ],
1530                "sample_terms": [
1531                    {
1532                        "@id": "/sample-terms/EFO_0002796/",
1533                        "status": "released",
1534                        "term_name": "Jurkat"
1535                    }
1536                ],
1537                "status": "released",
1538                "summary": "Homo sapiens (male) Jurkat cell line (sorting details: FACS bin for 90-100% expression of PPIF) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
1539                "taxa": "Homo sapiens",
1540                "treatments": [
1541                    {
1542                        "@id": "/treatments/df02c0d4-f796-4f77-bfbc-388cdbfcc615/",
1543                        "purpose": "stimulation",
1544                        "status": "released",
1545                        "summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours",
1546                        "treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
1547                    },
1548                    {
1549                        "@id": "/treatments/42b3c61d-38de-4bd2-bb39-33c125a417cb/",
1550                        "purpose": "stimulation",
1551                        "status": "released",
1552                        "summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours",
1553                        "treatment_term_name": "phorbol 13-acetate 12-myristate"
1554                    }
1555                ]
1556            },
1557            {
1558                "@id": "/in-vitro-systems/IGVFSM9089XQVC/",
1559                "@type": [
1560                    "InVitroSystem",
1561                    "Biosample",
1562                    "Sample",
1563                    "Item"
1564                ],
1565                "accession": "IGVFSM9089XQVC",
1566                "classifications": [
1567                    "cell line"
1568                ],
1569                "modifications": [
1570                    {
1571                        "@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
1572                        "modality": "prime editing",
1573                        "status": "released",
1574                        "summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
1575                    }
1576                ],
1577                "sample_terms": [
1578                    {
1579                        "@id": "/sample-terms/EFO_0002796/",
1580                        "status": "released",
1581                        "term_name": "Jurkat"
1582                    }
1583                ],
1584                "status": "released",
1585                "summary": "Homo sapiens (male) Jurkat cell line (sorting details: FACS bin for 0-10% expression of PPIF) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
1586                "taxa": "Homo sapiens",
1587                "treatments": [
1588                    {
1589                        "@id": "/treatments/df02c0d4-f796-4f77-bfbc-388cdbfcc615/",
1590                        "purpose": "stimulation",
1591                        "status": "released",
1592                        "summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours",
1593                        "treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
1594                    },
1595                    {
1596                        "@id": "/treatments/42b3c61d-38de-4bd2-bb39-33c125a417cb/",
1597                        "purpose": "stimulation",
1598                        "status": "released",
1599                        "summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours",
1600                        "treatment_term_name": "phorbol 13-acetate 12-myristate"
1601                    }
1602                ]
1603            },
1604            {
1605                "@id": "/in-vitro-systems/IGVFSM5179ONAU/",
1606                "@type": [
1607                    "InVitroSystem",
1608                    "Biosample",
1609                    "Sample",
1610                    "Item"
1611                ],
1612                "accession": "IGVFSM5179ONAU",
1613                "classifications": [
1614                    "cell line"
1615                ],
1616                "modifications": [
1617                    {
1618                        "@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
1619                        "modality": "prime editing",
1620                        "status": "released",
1621                        "summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
1622                    }
1623                ],
1624                "sample_terms": [
1625                    {
1626                        "@id": "/sample-terms/EFO_0002796/",
1627                        "status": "released",
1628                        "term_name": "Jurkat"
1629                    }
1630                ],
1631                "status": "released",
1632                "summary": "Homo sapiens (male) Jurkat cell line (sorting details: FACS bin for 11-20% expression of PPIF) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
1633                "taxa": "Homo sapiens",
1634                "treatments": [
1635                    {
1636                        "@id": "/treatments/df02c0d4-f796-4f77-bfbc-388cdbfcc615/",
1637                        "purpose": "stimulation",
1638                        "status": "released",
1639                        "summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours",
1640                        "treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
1641                    },
1642                    {
1643                        "@id": "/treatments/42b3c61d-38de-4bd2-bb39-33c125a417cb/",
1644                        "purpose": "stimulation",
1645                        "status": "released",
1646                        "summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours",
1647                        "treatment_term_name": "phorbol 13-acetate 12-myristate"
1648                    }
1649                ]
1650            },
1651            {
1652                "@id": "/in-vitro-systems/IGVFSM9972NTOV/",
1653                "@type": [
1654                    "InVitroSystem",
1655                    "Biosample",
1656                    "Sample",
1657                    "Item"
1658                ],
1659                "accession": "IGVFSM9972NTOV",
1660                "classifications": [
1661                    "cell line"
1662                ],
1663                "modifications": [
1664                    {
1665                        "@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
1666                        "modality": "prime editing",
1667                        "status": "released",
1668                        "summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
1669                    }
1670                ],
1671                "sample_terms": [
1672                    {
1673                        "@id": "/sample-terms/EFO_0002796/",
1674                        "status": "released",
1675                        "term_name": "Jurkat"
1676                    }
1677                ],
1678                "status": "released",
1679                "summary": "Homo sapiens (male) Jurkat cell line treated with 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
1680                "taxa": "Homo sapiens",
1681                "treatments": [
1682                    {
1683                        "@id": "/treatments/df02c0d4-f796-4f77-bfbc-388cdbfcc615/",
1684                        "purpose": "stimulation",
1685                        "status": "released",
1686                        "summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours",
1687                        "treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
1688                    },
1689                    {
1690                        "@id": "/treatments/42b3c61d-38de-4bd2-bb39-33c125a417cb/",
1691                        "purpose": "stimulation",
1692                        "status": "released",
1693                        "summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours",
1694                        "treatment_term_name": "phorbol 13-acetate 12-myristate"
1695                    }
1696                ]
1697            },
1698            {
1699                "@id": "/in-vitro-systems/IGVFSM3571ZCFS/",
1700                "@type": [
1701                    "InVitroSystem",
1702                    "Biosample",
1703                    "Sample",
1704                    "Item"
1705                ],
1706                "accession": "IGVFSM3571ZCFS",
1707                "classifications": [
1708                    "cell line"
1709                ],
1710                "modifications": [
1711                    {
1712                        "@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
1713                        "modality": "prime editing",
1714                        "status": "released",
1715                        "summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
1716                    }
1717                ],
1718                "sample_terms": [
1719                    {
1720                        "@id": "/sample-terms/EFO_0002796/",
1721                        "status": "released",
1722                        "term_name": "Jurkat"
1723                    }
1724                ],
1725                "status": "released",
1726                "summary": "Homo sapiens (male) Jurkat cell line (sorting details: FACS bin for 80-90% expression of PPIF) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
1727                "taxa": "Homo sapiens",
1728                "treatments": [
1729                    {
1730                        "@id": "/treatments/df02c0d4-f796-4f77-bfbc-388cdbfcc615/",
1731                        "purpose": "stimulation",
1732                        "status": "released",
1733                        "summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours",
1734                        "treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
1735                    },
1736                    {
1737                        "@id": "/treatments/42b3c61d-38de-4bd2-bb39-33c125a417cb/",
1738                        "purpose": "stimulation",
1739                        "status": "released",
1740                        "summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours",
1741                        "treatment_term_name": "phorbol 13-acetate 12-myristate"
1742                    }
1743                ]
1744            },
1745            {
1746                "@id": "/in-vitro-systems/IGVFSM1668WFEU/",
1747                "@type": [
1748                    "InVitroSystem",
1749                    "Biosample",
1750                    "Sample",
1751                    "Item"
1752                ],
1753                "accession": "IGVFSM1668WFEU",
1754                "classifications": [
1755                    "cell line"
1756                ],
1757                "modifications": [
1758                    {
1759                        "@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
1760                        "modality": "prime editing",
1761                        "status": "released",
1762                        "summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
1763                    }
1764                ],
1765                "sample_terms": [
1766                    {
1767                        "@id": "/sample-terms/EFO_0002796/",
1768                        "status": "released",
1769                        "term_name": "Jurkat"
1770                    }
1771                ],
1772                "status": "released",
1773                "summary": "Homo sapiens (male) Jurkat cell line (sorting details: FACS bin for 11-20% expression of PPIF) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
1774                "taxa": "Homo sapiens",
1775                "treatments": [
1776                    {
1777                        "@id": "/treatments/df02c0d4-f796-4f77-bfbc-388cdbfcc615/",
1778                        "purpose": "stimulation",
1779                        "status": "released",
1780                        "summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours",
1781                        "treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
1782                    },
1783                    {
1784                        "@id": "/treatments/42b3c61d-38de-4bd2-bb39-33c125a417cb/",
1785                        "purpose": "stimulation",
1786                        "status": "released",
1787                        "summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours",
1788                        "treatment_term_name": "phorbol 13-acetate 12-myristate"
1789                    }
1790                ]
1791            },
1792            {
1793                "@id": "/in-vitro-systems/IGVFSM7955HHRE/",
1794                "@type": [
1795                    "InVitroSystem",
1796                    "Biosample",
1797                    "Sample",
1798                    "Item"
1799                ],
1800                "accession": "IGVFSM7955HHRE",
1801                "classifications": [
1802                    "cell line"
1803                ],
1804                "modifications": [
1805                    {
1806                        "@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
1807                        "modality": "prime editing",
1808                        "status": "released",
1809                        "summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
1810                    }
1811                ],
1812                "sample_terms": [
1813                    {
1814                        "@id": "/sample-terms/EFO_0002796/",
1815                        "status": "released",
1816                        "term_name": "Jurkat"
1817                    }
1818                ],
1819                "status": "released",
1820                "summary": "Homo sapiens (male) Jurkat cell line (sorting details: FACS bin for 11-20% expression of PPIF) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
1821                "taxa": "Homo sapiens",
1822                "treatments": [
1823                    {
1824                        "@id": "/treatments/df02c0d4-f796-4f77-bfbc-388cdbfcc615/",
1825                        "purpose": "stimulation",
1826                        "status": "released",
1827                        "summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours",
1828                        "treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
1829                    },
1830                    {
1831                        "@id": "/treatments/42b3c61d-38de-4bd2-bb39-33c125a417cb/",
1832                        "purpose": "stimulation",
1833                        "status": "released",
1834                        "summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours",
1835                        "treatment_term_name": "phorbol 13-acetate 12-myristate"
1836                    }
1837                ]
1838            },
1839            {
1840                "@id": "/in-vitro-systems/IGVFSM5829EVGX/",
1841                "@type": [
1842                    "InVitroSystem",
1843                    "Biosample",
1844                    "Sample",
1845                    "Item"
1846                ],
1847                "accession": "IGVFSM5829EVGX",
1848                "classifications": [
1849                    "cell line"
1850                ],
1851                "modifications": [
1852                    {
1853                        "@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
1854                        "modality": "prime editing",
1855                        "status": "released",
1856                        "summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
1857                    }
1858                ],
1859                "sample_terms": [
1860                    {
1861                        "@id": "/sample-terms/EFO_0002796/",
1862                        "status": "released",
1863                        "term_name": "Jurkat"
1864                    }
1865                ],
1866                "status": "released",
1867                "summary": "Homo sapiens (male) Jurkat cell line (sorting details: FACS bin for 35-45% expression of PPIF) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
1868                "taxa": "Homo sapiens",
1869                "treatments": [
1870                    {
1871                        "@id": "/treatments/df02c0d4-f796-4f77-bfbc-388cdbfcc615/",
1872                        "purpose": "stimulation",
1873                        "status": "released",
1874                        "summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours",
1875                        "treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
1876                    },
1877                    {
1878                        "@id": "/treatments/42b3c61d-38de-4bd2-bb39-33c125a417cb/",
1879                        "purpose": "stimulation",
1880                        "status": "released",
1881                        "summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours",
1882                        "treatment_term_name": "phorbol 13-acetate 12-myristate"
1883                    }
1884                ]
1885            },
1886            {
1887                "@id": "/in-vitro-systems/IGVFSM6662LPXP/",
1888                "@type": [
1889                    "InVitroSystem",
1890                    "Biosample",
1891                    "Sample",
1892                    "Item"
1893                ],
1894                "accession": "IGVFSM6662LPXP",
1895                "classifications": [
1896                    "cell line"
1897                ],
1898                "modifications": [
1899                    {
1900                        "@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
1901                        "modality": "prime editing",
1902                        "status": "released",
1903                        "summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
1904                    }
1905                ],
1906                "sample_terms": [
1907                    {
1908                        "@id": "/sample-terms/EFO_0002796/",
1909                        "status": "released",
1910                        "term_name": "Jurkat"
1911                    }
1912                ],
1913                "status": "released",
1914                "summary": "Homo sapiens (male) Jurkat cell line (sorting details: FACS bin for 35-45% expression of PPIF) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
1915                "taxa": "Homo sapiens",
1916                "treatments": [
1917                    {
1918                        "@id": "/treatments/df02c0d4-f796-4f77-bfbc-388cdbfcc615/",
1919                        "purpose": "stimulation",
1920                        "status": "released",
1921                        "summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours",
1922                        "treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
1923                    },
1924                    {
1925                        "@id": "/treatments/42b3c61d-38de-4bd2-bb39-33c125a417cb/",
1926                        "purpose": "stimulation",
1927                        "status": "released",
1928                        "summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours",
1929                        "treatment_term_name": "phorbol 13-acetate 12-myristate"
1930                    }
1931                ]
1932            },
1933            {
1934                "@id": "/in-vitro-systems/IGVFSM6938ZJAF/",
1935                "@type": [
1936                    "InVitroSystem",
1937                    "Biosample",
1938                    "Sample",
1939                    "Item"
1940                ],
1941                "accession": "IGVFSM6938ZJAF",
1942                "classifications": [
1943                    "cell line"
1944                ],
1945                "modifications": [
1946                    {
1947                        "@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
1948                        "modality": "prime editing",
1949                        "status": "released",
1950                        "summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
1951                    }
1952                ],
1953                "sample_terms": [
1954                    {
1955                        "@id": "/sample-terms/EFO_0002796/",
1956                        "status": "released",
1957                        "term_name": "Jurkat"
1958                    }
1959                ],
1960                "status": "released",
1961                "summary": "Homo sapiens (male) Jurkat cell line (sorting details: FACS bin for 90-100% expression of PPIF) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
1962                "taxa": "Homo sapiens",
1963                "treatments": [
1964                    {
1965                        "@id": "/treatments/df02c0d4-f796-4f77-bfbc-388cdbfcc615/",
1966                        "purpose": "stimulation",
1967                        "status": "released",
1968                        "summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours",
1969                        "treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
1970                    },
1971                    {
1972                        "@id": "/treatments/42b3c61d-38de-4bd2-bb39-33c125a417cb/",
1973                        "purpose": "stimulation",
1974                        "status": "released",
1975                        "summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours",
1976                        "treatment_term_name": "phorbol 13-acetate 12-myristate"
1977                    }
1978                ]
1979            },
1980            {
1981                "@id": "/in-vitro-systems/IGVFSM2681JPHQ/",
1982                "@type": [
1983                    "InVitroSystem",
1984                    "Biosample",
1985                    "Sample",
1986                    "Item"
1987                ],
1988                "accession": "IGVFSM2681JPHQ",
1989                "classifications": [
1990                    "cell line"
1991                ],
1992                "modifications": [
1993                    {
1994                        "@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
1995                        "modality": "prime editing",
1996                        "status": "released",
1997                        "summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
1998                    }
1999                ],
2000                "sample_terms": [
2001                    {
2002                        "@id": "/sample-terms/EFO_0002796/",
2003                        "status": "released",
2004                        "term_name": "Jurkat"
2005                    }
2006                ],
2007                "status": "released",
2008                "summary": "Homo sapiens (male) Jurkat cell line (sorting details: FACS bin for 0-10% expression of PPIF) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
2009                "taxa": "Homo sapiens",
2010                "treatments": [
2011                    {
2012                        "@id": "/treatments/df02c0d4-f796-4f77-bfbc-388cdbfcc615/",
2013                        "purpose": "stimulation",
2014                        "status": "released",
2015                        "summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours",
2016                        "treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
2017                    },
2018                    {
2019                        "@id": "/treatments/42b3c61d-38de-4bd2-bb39-33c125a417cb/",
2020                        "purpose": "stimulation",
2021                        "status": "released",
2022                        "summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours",
2023                        "treatment_term_name": "phorbol 13-acetate 12-myristate"
2024                    }
2025                ]
2026            },
2027            {
2028                "@id": "/in-vitro-systems/IGVFSM2030BXGE/",
2029                "@type": [
2030                    "InVitroSystem",
2031                    "Biosample",
2032                    "Sample",
2033                    "Item"
2034                ],
2035                "accession": "IGVFSM2030BXGE",
2036                "classifications": [
2037                    "cell line"
2038                ],
2039                "modifications": [
2040                    {
2041                        "@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
2042                        "modality": "prime editing",
2043                        "status": "released",
2044                        "summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
2045                    }
2046                ],
2047                "sample_terms": [
2048                    {
2049                        "@id": "/sample-terms/EFO_0002796/",
2050                        "status": "released",
2051                        "term_name": "Jurkat"
2052                    }
2053                ],
2054                "status": "released",
2055                "summary": "Homo sapiens (male) Jurkat cell line (sorting details: FACS bin for 90-100% expression of PPIF) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
2056                "taxa": "Homo sapiens",
2057                "treatments": [
2058                    {
2059                        "@id": "/treatments/df02c0d4-f796-4f77-bfbc-388cdbfcc615/",
2060                        "purpose": "stimulation",
2061                        "status": "released",
2062                        "summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours",
2063                        "treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
2064                    },
2065                    {
2066                        "@id": "/treatments/42b3c61d-38de-4bd2-bb39-33c125a417cb/",
2067                        "purpose": "stimulation",
2068                        "status": "released",
2069                        "summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours",
2070                        "treatment_term_name": "phorbol 13-acetate 12-myristate"
2071                    }
2072                ]
2073            },
2074            {
2075                "@id": "/in-vitro-systems/IGVFSM6920JBXJ/",
2076                "@type": [
2077                    "InVitroSystem",
2078                    "Biosample",
2079                    "Sample",
2080                    "Item"
2081                ],
2082                "accession": "IGVFSM6920JBXJ",
2083                "classifications": [
2084                    "cell line"
2085                ],
2086                "modifications": [
2087                    {
2088                        "@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
2089                        "modality": "prime editing",
2090                        "status": "released",
2091                        "summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
2092                    }
2093                ],
2094                "sample_terms": [
2095                    {
2096                        "@id": "/sample-terms/EFO_0002796/",
2097                        "status": "released",
2098                        "term_name": "Jurkat"
2099                    }
2100                ],
2101                "status": "released",
2102                "summary": "Homo sapiens (male) Jurkat cell line (sorting details: FACS bin for 0-10% expression of PPIF) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
2103                "taxa": "Homo sapiens",
2104                "treatments": [
2105                    {
2106                        "@id": "/treatments/df02c0d4-f796-4f77-bfbc-388cdbfcc615/",
2107                        "purpose": "stimulation",
2108                        "status": "released",
2109                        "summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours",
2110                        "treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
2111                    },
2112                    {
2113                        "@id": "/treatments/42b3c61d-38de-4bd2-bb39-33c125a417cb/",
2114                        "purpose": "stimulation",
2115                        "status": "released",
2116                        "summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours",
2117                        "treatment_term_name": "phorbol 13-acetate 12-myristate"
2118                    }
2119                ]
2120            },
2121            {
2122                "@id": "/in-vitro-systems/IGVFSM7782WCLX/",
2123                "@type": [
2124                    "InVitroSystem",
2125                    "Biosample",
2126                    "Sample",
2127                    "Item"
2128                ],
2129                "accession": "IGVFSM7782WCLX",
2130                "classifications": [
2131                    "cell line"
2132                ],
2133                "modifications": [
2134                    {
2135                        "@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
2136                        "modality": "prime editing",
2137                        "status": "released",
2138                        "summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
2139                    }
2140                ],
2141                "sample_terms": [
2142                    {
2143                        "@id": "/sample-terms/EFO_0002796/",
2144                        "status": "released",
2145                        "term_name": "Jurkat"
2146                    }
2147                ],
2148                "status": "released",
2149                "summary": "Homo sapiens (male) Jurkat cell line (sorting details: FACS bin for 90-100% expression of PPIF) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
2150                "taxa": "Homo sapiens",
2151                "treatments": [
2152                    {
2153                        "@id": "/treatments/df02c0d4-f796-4f77-bfbc-388cdbfcc615/",
2154                        "purpose": "stimulation",
2155                        "status": "released",
2156                        "summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours",
2157                        "treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
2158                    },
2159                    {
2160                        "@id": "/treatments/42b3c61d-38de-4bd2-bb39-33c125a417cb/",
2161                        "purpose": "stimulation",
2162                        "status": "released",
2163                        "summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours",
2164                        "treatment_term_name": "phorbol 13-acetate 12-myristate"
2165                    }
2166                ]
2167            },
2168            {
2169                "@id": "/in-vitro-systems/IGVFSM0193KFOU/",
2170                "@type": [
2171                    "InVitroSystem",
2172                    "Biosample",
2173                    "Sample",
2174                    "Item"
2175                ],
2176                "accession": "IGVFSM0193KFOU",
2177                "classifications": [
2178                    "cell line"
2179                ],
2180                "modifications": [
2181                    {
2182                        "@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
2183                        "modality": "prime editing",
2184                        "status": "released",
2185                        "summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
2186                    }
2187                ],
2188                "sample_terms": [
2189                    {
2190                        "@id": "/sample-terms/EFO_0002796/",
2191                        "status": "released",
2192                        "term_name": "Jurkat"
2193                    }
2194                ],
2195                "status": "released",
2196                "summary": "Homo sapiens (male) Jurkat cell line treated with 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
2197                "taxa": "Homo sapiens",
2198                "treatments": [
2199                    {
2200                        "@id": "/treatments/df02c0d4-f796-4f77-bfbc-388cdbfcc615/",
2201                        "purpose": "stimulation",
2202                        "status": "released",
2203                        "summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours",
2204                        "treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
2205                    },
2206                    {
2207                        "@id": "/treatments/42b3c61d-38de-4bd2-bb39-33c125a417cb/",
2208                        "purpose": "stimulation",
2209                        "status": "released",
2210                        "summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours",
2211                        "treatment_term_name": "phorbol 13-acetate 12-myristate"
2212                    }
2213                ]
2214            },
2215            {
2216                "@id": "/in-vitro-systems/IGVFSM7762ZCFL/",
2217                "@type": [
2218                    "InVitroSystem",
2219                    "Biosample",
2220                    "Sample",
2221                    "Item"
2222                ],
2223                "accession": "IGVFSM7762ZCFL",
2224                "classifications": [
2225                    "cell line"
2226                ],
2227                "modifications": [
2228                    {
2229                        "@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
2230                        "modality": "prime editing",
2231                        "status": "released",
2232                        "summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
2233                    }
2234                ],
2235                "sample_terms": [
2236                    {
2237                        "@id": "/sample-terms/EFO_0002796/",
2238                        "status": "released",
2239                        "term_name": "Jurkat"
2240                    }
2241                ],
2242                "status": "released",
2243                "summary": "Homo sapiens (male) Jurkat cell line (sorting details: FACS bin for 90-100% expression of PPIF) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
2244                "taxa": "Homo sapiens",
2245                "treatments": [
2246                    {
2247                        "@id": "/treatments/df02c0d4-f796-4f77-bfbc-388cdbfcc615/",
2248                        "purpose": "stimulation",
2249                        "status": "released",
2250                        "summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours",
2251                        "treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
2252                    },
2253                    {
2254                        "@id": "/treatments/42b3c61d-38de-4bd2-bb39-33c125a417cb/",
2255                        "purpose": "stimulation",
2256                        "status": "released",
2257                        "summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours",
2258                        "treatment_term_name": "phorbol 13-acetate 12-myristate"
2259                    }
2260                ]
2261            },
2262            {
2263                "@id": "/in-vitro-systems/IGVFSM7199PIWN/",
2264                "@type": [
2265                    "InVitroSystem",
2266                    "Biosample",
2267                    "Sample",
2268                    "Item"
2269                ],
2270                "accession": "IGVFSM7199PIWN",
2271                "classifications": [
2272                    "cell line"
2273                ],
2274                "modifications": [
2275                    {
2276                        "@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
2277                        "modality": "prime editing",
2278                        "status": "released",
2279                        "summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
2280                    }
2281                ],
2282                "sample_terms": [
2283                    {
2284                        "@id": "/sample-terms/EFO_0002796/",
2285                        "status": "released",
2286                        "term_name": "Jurkat"
2287                    }
2288                ],
2289                "status": "released",
2290                "summary": "Homo sapiens (male) Jurkat cell line (sorting details: FACS bin for 0-10% expression of PPIF) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
2291                "taxa": "Homo sapiens",
2292                "treatments": [
2293                    {
2294                        "@id": "/treatments/df02c0d4-f796-4f77-bfbc-388cdbfcc615/",
2295                        "purpose": "stimulation",
2296                        "status": "released",
2297                        "summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours",
2298                        "treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
2299                    },
2300                    {
2301                        "@id": "/treatments/42b3c61d-38de-4bd2-bb39-33c125a417cb/",
2302                        "purpose": "stimulation",
2303                        "status": "released",
2304                        "summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours",
2305                        "treatment_term_name": "phorbol 13-acetate 12-myristate"
2306                    }
2307                ]
2308            },
2309            {
2310                "@id": "/in-vitro-systems/IGVFSM4844JJJX/",
2311                "@type": [
2312                    "InVitroSystem",
2313                    "Biosample",
2314                    "Sample",
2315                    "Item"
2316                ],
2317                "accession": "IGVFSM4844JJJX",
2318                "classifications": [
2319                    "cell line"
2320                ],
2321                "modifications": [
2322                    {
2323                        "@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
2324                        "modality": "prime editing",
2325                        "status": "released",
2326                        "summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
2327                    }
2328                ],
2329                "sample_terms": [
2330                    {
2331                        "@id": "/sample-terms/EFO_0002796/",
2332                        "status": "released",
2333                        "term_name": "Jurkat"
2334                    }
2335                ],
2336                "status": "released",
2337                "summary": "Homo sapiens (male) Jurkat cell line (sorting details: FACS bin for 55-65% expression of PPIF) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
2338                "taxa": "Homo sapiens",
2339                "treatments": [
2340                    {
2341                        "@id": "/treatments/df02c0d4-f796-4f77-bfbc-388cdbfcc615/",
2342                        "purpose": "stimulation",
2343                        "status": "released",
2344                        "summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours",
2345                        "treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
2346                    },
2347                    {
2348                        "@id": "/treatments/42b3c61d-38de-4bd2-bb39-33c125a417cb/",
2349                        "purpose": "stimulation",
2350                        "status": "released",
2351                        "summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours",
2352                        "treatment_term_name": "phorbol 13-acetate 12-myristate"
2353                    }
2354                ]
2355            },
2356            {
2357                "@id": "/in-vitro-systems/IGVFSM4221WRQS/",
2358                "@type": [
2359                    "InVitroSystem",
2360                    "Biosample",
2361                    "Sample",
2362                    "Item"
2363                ],
2364                "accession": "IGVFSM4221WRQS",
2365                "classifications": [
2366                    "cell line"
2367                ],
2368                "modifications": [
2369                    {
2370                        "@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
2371                        "modality": "prime editing",
2372                        "status": "released",
2373                        "summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
2374                    }
2375                ],
2376                "sample_terms": [
2377                    {
2378                        "@id": "/sample-terms/EFO_0002796/",
2379                        "status": "released",
2380                        "term_name": "Jurkat"
2381                    }
2382                ],
2383                "status": "released",
2384                "summary": "Homo sapiens (male) Jurkat cell line (sorting details: FACS bin for 55-65% expression of PPIF) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
2385                "taxa": "Homo sapiens",
2386                "treatments": [
2387                    {
2388                        "@id": "/treatments/df02c0d4-f796-4f77-bfbc-388cdbfcc615/",
2389                        "purpose": "stimulation",
2390                        "status": "released",
2391                        "summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours",
2392                        "treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
2393                    },
2394                    {
2395                        "@id": "/treatments/42b3c61d-38de-4bd2-bb39-33c125a417cb/",
2396                        "purpose": "stimulation",
2397                        "status": "released",
2398                        "summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours",
2399                        "treatment_term_name": "phorbol 13-acetate 12-myristate"
2400                    }
2401                ]
2402            },
2403            {
2404                "@id": "/in-vitro-systems/IGVFSM7796ITHX/",
2405                "@type": [
2406                    "InVitroSystem",
2407                    "Biosample",
2408                    "Sample",
2409                    "Item"
2410                ],
2411                "accession": "IGVFSM7796ITHX",
2412                "classifications": [
2413                    "cell line"
2414                ],
2415                "modifications": [
2416                    {
2417                        "@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
2418                        "modality": "prime editing",
2419                        "status": "released",
2420                        "summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
2421                    }
2422                ],
2423                "sample_terms": [
2424                    {
2425                        "@id": "/sample-terms/EFO_0002796/",
2426                        "status": "released",
2427                        "term_name": "Jurkat"
2428                    }
2429                ],
2430                "status": "released",
2431                "summary": "Homo sapiens (male) Jurkat cell line (sorting details: FACS bin for 35-45% expression of PPIF) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
2432                "taxa": "Homo sapiens",
2433                "treatments": [
2434                    {
2435                        "@id": "/treatments/df02c0d4-f796-4f77-bfbc-388cdbfcc615/",
2436                        "purpose": "stimulation",
2437                        "status": "released",
2438                        "summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours",
2439                        "treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
2440                    },
2441                    {
2442                        "@id": "/treatments/42b3c61d-38de-4bd2-bb39-33c125a417cb/",
2443                        "purpose": "stimulation",
2444                        "status": "released",
2445                        "summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours",
2446                        "treatment_term_name": "phorbol 13-acetate 12-myristate"
2447                    }
2448                ]
2449            },
2450            {
2451                "@id": "/in-vitro-systems/IGVFSM2342HMUU/",
2452                "@type": [
2453                    "InVitroSystem",
2454                    "Biosample",
2455                    "Sample",
2456                    "Item"
2457                ],
2458                "accession": "IGVFSM2342HMUU",
2459                "classifications": [
2460                    "cell line"
2461                ],
2462                "modifications": [
2463                    {
2464                        "@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
2465                        "modality": "prime editing",
2466                        "status": "released",
2467                        "summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
2468                    }
2469                ],
2470                "sample_terms": [
2471                    {
2472                        "@id": "/sample-terms/EFO_0002796/",
2473                        "status": "released",
2474                        "term_name": "Jurkat"
2475                    }
2476                ],
2477                "status": "released",
2478                "summary": "Homo sapiens (male) Jurkat cell line (sorting details: FACS bin for 11-20% expression of PPIF) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
2479                "taxa": "Homo sapiens",
2480                "treatments": [
2481                    {
2482                        "@id": "/treatments/df02c0d4-f796-4f77-bfbc-388cdbfcc615/",
2483                        "purpose": "stimulation",
2484                        "status": "released",
2485                        "summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours",
2486                        "treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
2487                    },
2488                    {
2489                        "@id": "/treatments/42b3c61d-38de-4bd2-bb39-33c125a417cb/",
2490                        "purpose": "stimulation",
2491                        "status": "released",
2492                        "summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours",
2493                        "treatment_term_name": "phorbol 13-acetate 12-myristate"
2494                    }
2495                ]
2496            },
2497            {
2498                "@id": "/in-vitro-systems/IGVFSM1865XXUT/",
2499                "@type": [
2500                    "InVitroSystem",
2501                    "Biosample",
2502                    "Sample",
2503                    "Item"
2504                ],
2505                "accession": "IGVFSM1865XXUT",
2506                "classifications": [
2507                    "cell line"
2508                ],
2509                "modifications": [
2510                    {
2511                        "@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
2512                        "modality": "prime editing",
2513                        "status": "released",
2514                        "summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
2515                    }
2516                ],
2517                "sample_terms": [
2518                    {
2519                        "@id": "/sample-terms/EFO_0002796/",
2520                        "status": "released",
2521                        "term_name": "Jurkat"
2522                    }
2523                ],
2524                "status": "released",
2525                "summary": "Homo sapiens (male) Jurkat cell line (sorting details: FACS bin for 55-65% expression of PPIF) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
2526                "taxa": "Homo sapiens",
2527                "treatments": [
2528                    {
2529                        "@id": "/treatments/df02c0d4-f796-4f77-bfbc-388cdbfcc615/",
2530                        "purpose": "stimulation",
2531                        "status": "released",
2532                        "summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours",
2533                        "treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
2534                    },
2535                    {
2536                        "@id": "/treatments/42b3c61d-38de-4bd2-bb39-33c125a417cb/",
2537                        "purpose": "stimulation",
2538                        "status": "released",
2539                        "summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours",
2540                        "treatment_term_name": "phorbol 13-acetate 12-myristate"
2541                    }
2542                ]
2543            },
2544            {
2545                "@id": "/in-vitro-systems/IGVFSM5748NPYI/",
2546                "@type": [
2547                    "InVitroSystem",
2548                    "Biosample",
2549                    "Sample",
2550                    "Item"
2551                ],
2552                "accession": "IGVFSM5748NPYI",
2553                "classifications": [
2554                    "cell line"
2555                ],
2556                "modifications": [
2557                    {
2558                        "@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
2559                        "modality": "prime editing",
2560                        "status": "released",
2561                        "summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
2562                    }
2563                ],
2564                "sample_terms": [
2565                    {
2566                        "@id": "/sample-terms/EFO_0002796/",
2567                        "status": "released",
2568                        "term_name": "Jurkat"
2569                    }
2570                ],
2571                "status": "released",
2572                "summary": "Homo sapiens (male) Jurkat cell line treated with 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
2573                "taxa": "Homo sapiens",
2574                "treatments": [
2575                    {
2576                        "@id": "/treatments/df02c0d4-f796-4f77-bfbc-388cdbfcc615/",
2577                        "purpose": "stimulation",
2578                        "status": "released",
2579                        "summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours",
2580                        "treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
2581                    },
2582                    {
2583                        "@id": "/treatments/42b3c61d-38de-4bd2-bb39-33c125a417cb/",
2584                        "purpose": "stimulation",
2585                        "status": "released",
2586                        "summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours",
2587                        "treatment_term_name": "phorbol 13-acetate 12-myristate"
2588                    }
2589                ]
2590            },
2591            {
2592                "@id": "/in-vitro-systems/IGVFSM2376QXPC/",
2593                "@type": [
2594                    "InVitroSystem",
2595                    "Biosample",
2596                    "Sample",
2597                    "Item"
2598                ],
2599                "accession": "IGVFSM2376QXPC",
2600                "classifications": [
2601                    "cell line"
2602                ],
2603                "modifications": [
2604                    {
2605                        "@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
2606                        "modality": "prime editing",
2607                        "status": "released",
2608                        "summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
2609                    }
2610                ],
2611                "sample_terms": [
2612                    {
2613                        "@id": "/sample-terms/EFO_0002796/",
2614                        "status": "released",
2615                        "term_name": "Jurkat"
2616                    }
2617                ],
2618                "status": "released",
2619                "summary": "Homo sapiens (male) Jurkat cell line treated with 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
2620                "taxa": "Homo sapiens",
2621                "treatments": [
2622                    {
2623                        "@id": "/treatments/df02c0d4-f796-4f77-bfbc-388cdbfcc615/",
2624                        "purpose": "stimulation",
2625                        "status": "released",
2626                        "summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours",
2627                        "treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
2628                    },
2629                    {
2630                        "@id": "/treatments/42b3c61d-38de-4bd2-bb39-33c125a417cb/",
2631                        "purpose": "stimulation",
2632                        "status": "released",
2633                        "summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours",
2634                        "treatment_term_name": "phorbol 13-acetate 12-myristate"
2635                    }
2636                ]
2637            },
2638            {
2639                "@id": "/in-vitro-systems/IGVFSM2875EBLI/",
2640                "@type": [
2641                    "InVitroSystem",
2642                    "Biosample",
2643                    "Sample",
2644                    "Item"
2645                ],
2646                "accession": "IGVFSM2875EBLI",
2647                "classifications": [
2648                    "cell line"
2649                ],
2650                "modifications": [
2651                    {
2652                        "@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
2653                        "modality": "prime editing",
2654                        "status": "released",
2655                        "summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
2656                    }
2657                ],
2658                "sample_terms": [
2659                    {
2660                        "@id": "/sample-terms/EFO_0002796/",
2661                        "status": "released",
2662                        "term_name": "Jurkat"
2663                    }
2664                ],
2665                "status": "released",
2666                "summary": "Homo sapiens (male) Jurkat cell line (sorting details: FACS bin for 11-20% expression of PPIF) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
2667                "taxa": "Homo sapiens",
2668                "treatments": [
2669                    {
2670                        "@id": "/treatments/df02c0d4-f796-4f77-bfbc-388cdbfcc615/",
2671                        "purpose": "stimulation",
2672                        "status": "released",
2673                        "summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 4 hours",
2674                        "treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
2675                    },
2676                    {
2677                        "@id": "/treatments/42b3c61d-38de-4bd2-bb39-33c125a417cb/",
2678                        "purpose": "stimulation",
2679                        "status": "released",
2680                        "summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 4 hours",
2681                        "treatment_term_name": "phorbol 13-acetate 12-myristate"
2682                    }
2683                ]
2684            }
2685        ],
2686        "status": "released",
2687        "summary": "CRISPR prime editing Variant-EFFECTS targeting PPIF integrating a guide (sgRNA) library targeting sequence variants in a genomic locus"
2688    },
2689    "file_size": 2567,
2690    "gene_list_for": [],
2691    "href": "/tabular-files/IGVFFI5753CWJL/@@download/IGVFFI5753CWJL.tsv.gz",
2692    "input_file_for": [],
2693    "integrated_in": [],
2694    "lab": {
2695        "@id": "/labs/jesse-engreitz/",
2696        "title": "Jesse Engreitz, Stanford"
2697    },
2698    "loci_list_for": [],
2699    "md5sum": "a86a994224303717c877d18dfed867f4",
2700    "primer_design_for": [],
2701    "quality_metrics": [],
2702    "s3_uri": "s3://igvf-files/2025/03/29/368ab1df-2350-4612-a367-d3dc7dd7b44c/IGVFFI5753CWJL.tsv.gz",
2703    "schema_version": "15",
2704    "status": "preview",
2705    "submitted_by": {
2706        "@id": "/users/f9e7cd82-a407-4a20-89ee-f4dc668b0cbe/",
2707        "title": "Michael Montgomery"
2708    },
2709    "submitted_file_name": "PPIF_promoter_8mer_insertion_Jurkat-Stimulation_VariantEffectsFile.tsv.gz",
2710    "submitter_comment": "The original outputs from the Variant-EFFECTS pipeline report VariantIDs in the hg19 format. To obtain the standardized variant information provided in this file, hg19 coordinates were lifted to hg38 using the UCSC LiftOver tool (https://genome.ucsc.edu/cgi-bin/hgLiftOver). Then, canonical, validated SPDIs were generated and validated using the igvf_spdi_demo tool (https://github.com/mikelove/igvf_spdi_demo).",
2711    "summary": "GRCh38 variant effects",
2712    "upload_status": "validated",
2713    "uuid": "368ab1df-2350-4612-a367-d3dc7dd7b44c"
2714}